Pharmacological characterization of a nonpeptide bradykinin B2receptor antagonist, FR165649, and agonist, FR190997
- 1 June 1998
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 124 (3) , 441-446
- https://doi.org/10.1038/sj.bjp.0701813
Abstract
1. The nonpeptide bradykinin (BK) B2 receptor antagonist, FR165649 (8-[2,6-dichloro-3-[N-[(E)-4-(N-methylcarbamoyl)cinnamidoacetyl ]-N-methylamino]benzyloxy]-2-methylquinoline), and agonist, FR190997 (8-[2,6-dichloro-3-[N-[(E)-4-(N-methylcarbamoyl) cinnamidoacetyl]-N-methylamino]benzyloxy]-2-methyl-4-(2-pyridyl methoxy)quinoline) have been identified. These compounds have a common chemical structure, and the 2-pyridylmethoxy group is the only structural difference between them. 2. Both FR165649 and FR190997 displaced [3H]-BK binding to B2 receptors in guinea-pig ileum membranes, with an IC50 of 4.7 x 10(-10) M and 1.5 x 10(-9) M, respectively. They also displaced [3H]-BK binding to B2 receptors in human lung fibroblast IMR-90 cells, with an IC50 of 1.6 x 10(-9) M and 9.8 x 10(-10) M, respectively. 3. In guinea-pig isolated ileum-preparations, FR165649 had no agonistic effect on contraction and caused parallel rightward shifts of the concentration-response curves to BK on contraction. Analysis of the data produced a nominal pA2 value of 9.2+/-0.1 (n=5) and a slope of 1.4+/-0.1 (n=5). On the other hand, FR190997 induced concentration-dependent contraction of guinea-pig ilea with a pD2 of 7.9+/-0.2 and the contraction was inhibited by a specific peptide bradykinin B2 receptor antagonist, Hoe 140 (D-Arg-[Hyp3, Thi5, D-Tic7, Oic8]BK) in a non-competitive manner. 4. In IMR-90 cells, FR165649 had no agonistic effect on phosphatidyl inositol (PI) hydrolysis and caused parallel rightward shifts (approximately 200 fold shift at 10(-7) M) of the concentration-response curves to BK on PI hydrolysis. FR190997 induced concentration-dependent PI hydrolysis in IMR-90 cells with a pD2 of 8.4+/-0.1, and this effect was inhibited by Hoe 140. 5. These results indicate that FR165649 and FR190997 are, respectively, a potent bradykinin B2 receptor antagonist and agonist, and that the agonistic activity depends on the small part of the nonpeptide ligand. FR165649 and FR190997 may be useful tools for studying the relationship between ligands and receptors.Keywords
This publication has 30 references indexed in Scilit:
- Effects of a nonpeptide bradykinin B2receptor antagonist, FR167344, on differentin vivoanimal models of inflammationBritish Journal of Pharmacology, 1997
- Nonpeptide Mimic of Bradykinin with Long-Acting Properties at the Bradykinin B2 ReceptorMolecular Pharmacology, 1997
- The identification of an orally active, nonpeptide bradykinin B2 receptor antagonist, FR173657British Journal of Pharmacology, 1997
- Novel Subtype-Selective Nonpeptide Bradykinin Receptor Antagonists FR167344 and FR173657Molecular Pharmacology, 1997
- Discovery of 1,5-Benzodiazepines with Peripheral Cholecystokinin (CCK-A) Receptor Agonist Activity. 1. Optimization of the Agonist “Trigger”Journal of Medicinal Chemistry, 1996
- A new class of bradykinin antagonists: synthesis and in vitro activity of bissuccinimidoalkane peptide dimersJournal of Medicinal Chemistry, 1992
- Bradykinin receptor antagonistsMedicinal Research Reviews, 1990
- Dissociation of bradykinin-induced prostaglandin formation from phosphatidylinositol turnover in Swiss 3T3 fibroblasts: evidence for G protein regulation of phospholipase A2.Proceedings of the National Academy of Sciences, 1987
- Changes in the levels of inositol phosphates after agonist-dependent hydrolysis of membrane phosphoinositidesBiochemical Journal, 1983
- Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reactionBiochemical Pharmacology, 1973